
Novo Nordisk: Poised for a Weighty Comeback in the Obesity Drug Arena
Novo Nordisk’s shares have dipped amid market volatility, yet the company’s outlook remains strong due to its weight loss drug, Wegovy. The obesity crisis is a growing global concern, affecting nearly half of the adult U.S. population and over 1 billion worldwide